Clinical Trials
68 trialsNEOS
Yonsei University
NeoCOAST-2
AstraZeneca
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma
Sohag University
TeLuRide-008
Eikon Therapeutics
MYSTIC
AstraZeneca
Appalaches
European Organisation for Research and Treatment of Cancer - EORTC
NEPTUNE
AstraZeneca
ACCRAPAN
Centre Oscar Lambret
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
George Washington University
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Jiangsu HengRui Medicine Co., Ltd.
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
PRIAM
The Netherlands Cancer Institute
DOMENICA
ARCAGY/ GINECO GROUP
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Camella
Blokhin's Russian Cancer Research Center
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
TNBC
Tata Memorial Hospital
NEEDS
Karolinska University Hospital
DUO-O
AstraZeneca
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
West China Hospital
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
POWERRANGER
CancerCare Manitoba
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc.
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
iCHRTL
Maria Sklodowska-Curie National Research Institute of Oncology
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
Cairo University
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Yale University
CheckMate 568
Bristol-Myers Squibb
Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
Fudan University
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Shandong Cancer Hospital and Institute
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
Shengjing Hospital
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer
Hunan Cancer Hospital
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
CTI BioPharma
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
Fudan University
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Japanese Gynecologic Oncology Group
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
Zhejiang Cancer Hospital
READ
Danish Breast Cancer Cooperative Group
QUIMERA
Instituto Nacional de Cancer, Brazil
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
Peregrine Pharmaceuticals
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
University of Alabama at Birmingham
NATT
Shanghai Jiao Tong University School of Medicine
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)
King Faisal Specialist Hospital & Research Center
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics